Combination therapy in hypertension: An update

被引:0
作者
Sanjay Kalra
Bharti Kalra
Navneet Agrawal
机构
[1] Bharti Hospital,Dept of Endocrinology
[2] Bharti Hospital,Dept of Gynaecology
[3] GR Medical College,Dept of Medicine
来源
Diabetology & Metabolic Syndrome | / 2卷
关键词
Chronic Heart Failure; Amlodipine; Carvedilol; Felodipine; Candesartan;
D O I
暂无
中图分类号
学科分类号
摘要
Meticulous control of blood pressure is required in patients with hypertension to produce the maximum reduction in clinical cardiovascular end points, especially in patients with comorbidities like diabetes mellitus where more aggressive blood pressure lowering might be beneficial. Recent clinical trials suggest that the approach of using monotherapy for the control of hypertension is not likely to be successful in most patients. Combination therapy may be theoretically favored by the fact that multiple factors contribute to hypertension, and achieving control of blood pressure with single agent acting through one particular mechanism may not be possible. Regimens can either be fixed dose combinations or drugs added sequentially one after other. Combining the drugs makes them available in a convenient dosing format, lower the dose of individual component, thus, reducing the side effects and improving compliance. Classes of antihypertensive agents which have been commonly used are angiotensin receptor blockers, thiazide diuretics, beta and alpha blockers, calcium antagonists and angiotensin-converting enzyme inhibitors. Thiazide diuretics and calcium channel blockers are effective, as well as combinations that include renin-angiotensin-aldosterone system blockers, in reducing BP. The majority of currently available fixed-dose combinations are diuretic-based. Combinations may be individualized according to the presence of comorbidities like diabetes mellitus, chronic renal failure, heart failure, thyroid disorders and for special population groups like elderly and pregnant females.
引用
收藏
相关论文
共 447 条
[61]  
Westerling S(2005)Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes Diabetes Care 28 737-376
[62]  
Littlejohn TW(2007)Effect of Telmisartan on Cholesterol Levels in Patients with Hypertension - Saga Telmisartan Aggressive Research (STAR) Horm Metab Res 39 372-3452
[63]  
Majul CR(2005)Molecular characterization of new selective peroxisome proliferators-activated receptor γ modulators with angiotensine receptor blocking activity Diabetes 54 3442-1455
[64]  
Olvera R(1995)Overview of randomized trials of angiotensin-converting enzyme inhibitors on the mortality and morbidity in patients with heart failure JAMA 18 1450-210
[65]  
Seeber M(1999)Beta-blockers in heart failure. The 'new wave' of clinical trials Drugs 58 203-1429
[66]  
Kobe M(2004)Carvedilol Prospective Randomized Cumulative Survival Study Group. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study J Am Coll Cardiol 43 1423-771
[67]  
Guthrie R(2003)CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 767-553
[68]  
Oigman W(2008)Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial Lancet 372 547-501
[69]  
Sanford M(2006)Management of hypertension in chronic kidney disease Curr Hypertens Rep 8 497-75
[70]  
Keam SJ(2007)Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004 Hypertension 49 69-362